James J. Hsieh

James J. Hsieh, MD, PhD

  • Medical Oncology

Sees Patients For

Kidney cancer, rare kidney cancer, targeted therapy, immunotherapy, precision medicine

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital

Academic Title(s)

Professor, Oncology

Division of Medical Oncology
Molecular Oncology & Developmental Therapeutics

Languages

  • English
  • Mandarin
  • Taiwanese

Education

Fellowship, Medical Oncology

2003 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

Fellowship, Medical Oncology

2000 Washington University School of Medicine, St. Louis, MO

Residency, Internal Medicine

1999 Barnes-Jewish Hospital, St. Louis, MO

PhD, Molecular Biology

1996 Johns Hopkins University School of Medicine, Baltimore, MD

Medical Degree

1990 Taipei Medical University, Taipei, Taiwan

Research Interests

In 2011, Dr. Hsieh founded the Translational Kidney Cancer Research Program (TKCRP) to enable seamless collaboration among basic, preclinical and clinical scientists. The team employs state-of-art platforms and clinical trial materials to integrate kidney cancer genomics, transcriptomics, proteomics, metabolomics, and therapeutics. His group pioneered a novel metabolic analytic algorithm (Metabologram) to interrogate human cancer metabolism in 2016. His laboratory recently established novel kidney cancer mouse models that recapitulate prevalent human kidney cancer mutations. Through studying kidney cancer, Dr. Hsieh proposed a novel cancer evolution (braided cancer river) model in 2015, capitalizing phenotypically, mechanistically convergent events to guide effective cancer therapy and overcome treatment-resistance. His primary translational goals are to develop novel mechanism-based, personalized therapeutics to prevent recurrence in high-risk patients and provide cure to significant number of metastatic kidney cancer patients.

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: BostonGeneEquity: YesReporting Date: 05/01/2021